263 related articles for article (PubMed ID: 24803302)
1. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.
Pan WJ; Köck K; Rees WA; Sullivan BA; Evangelista CM; Yen M; Andrews JM; Radford-Smith GL; Prince PJ; Reynhardt KO; Doherty DR; Patel SK; Krill CD; Zhou K; Shen J; Smith LE; Gow JM; Lee J; Treacy AM; Yu Z; Platt VM; Borie DC
Br J Clin Pharmacol; 2014 Dec; 78(6):1315-33. PubMed ID: 24803302
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.
Pan WJ; Hsu H; Rees WA; Lear SP; Lee F; Foltz IN; Rathanaswami P; Manchulenko K; Chan BM; Zhang M; Xia XZ; Patel SK; Prince PJ; Doherty DR; Sheckler CM; Reynhardt KO; Krill CD; Harder BJ; Wisler JA; Brandvig JL; Lynch JL; Anderson AA; Wienkers LC; Borie DC
Br J Pharmacol; 2013 May; 169(1):51-68. PubMed ID: 23425116
[TBL] [Abstract][Full Text] [Related]
3. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S
Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454
[TBL] [Abstract][Full Text] [Related]
4. Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases.
Li H; Köck K; Wisler JA; Rees WA; Prince PJ; Reynhardt KO; Hsu H; Yu Z; Borie DC; Salinger DH; Pan WJ
Pharmacol Res Perspect; 2015 Feb; 3(1):e00098. PubMed ID: 25692016
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
van Hartingsveldt B; Nnane IP; Bouman-Thio E; Loza MJ; Piantone A; Davis HM; Petty KJ
Br J Clin Pharmacol; 2013 May; 75(5):1289-98. PubMed ID: 23043368
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W
Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of AMG 139, a human antibody specifically targeting IL-23.
Köck K; Pan WJ; Gow JM; Horner MJ; Gibbs JP; Colbert A; Goletz TJ; Newhall KJ; Rees WA; Sun Y; Zhang Y; O'Neill JC; Umble-Romero AN; Prokop SP; Krill CD; Som L; Buntich SA; Trimble MW; Tsuji WH; Towne JE
Br J Pharmacol; 2015 Jan; 172(1):159-72. PubMed ID: 25205227
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
[TBL] [Abstract][Full Text] [Related]
11. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
[TBL] [Abstract][Full Text] [Related]
13. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.
Bekker PJ; Holloway DL; Rasmussen AS; Murphy R; Martin SW; Leese PT; Holmes GB; Dunstan CR; DePaoli AM
J Bone Miner Res; 2004 Jul; 19(7):1059-66. PubMed ID: 15176987
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee.
Cohen SB; Proudman S; Kivitz AJ; Burch FX; Donohue JP; Burstein D; Sun YN; Banfield C; Vincent MS; Ni L; Zack DJ
Arthritis Res Ther; 2011 Jul; 13(4):R125. PubMed ID: 21801403
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Zhang W; Scalori A; Fuh F; McBride J; She G; Kierkus J; Korczowksi B; Li R; Abouhossein M; Kadva A; Park KT; Tang MT
Inflamm Bowel Dis; 2022 Sep; 28(9):1348-1356. PubMed ID: 34849918
[TBL] [Abstract][Full Text] [Related]
19. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
[TBL] [Abstract][Full Text] [Related]
20. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Padhi D; Jang G; Stouch B; Fang L; Posvar E
J Bone Miner Res; 2011 Jan; 26(1):19-26. PubMed ID: 20593411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
